Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The RECELL® System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells.
Product Name : RECELL
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 11, 2022
Lead Product(s) : Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enrollment of Pivotal trial for Recell (Regenerative Epidermal Suspension) is completed and topline result are expecting in the second half of 2022 for treatment of soft-tissue reconstruction.
Product Name : RECELL
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 01, 2022
Lead Product(s) : Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regenerative Epidermal Cell
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary effectiveness evaluation is based on a comparison of the incidence of successful repigmentation with RECELL versus that of a standard of care control. Long-term durability data (assessing sustained repigmentation over 52 weeks) will be collec...
Product Name : Recell
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Regenerative Epidermal Cell
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This study seeks to demonstrate that treatment with the RECELL System of partial-thickness burn injuries within 72-hours can safely increase the healing at day 10.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 03, 2020
Lead Product(s) : Autologous Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable